Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology.
FRONTIERS IN MEDICINE（2023）
Abstract
Our study found that the benefits of eltrombopag treatment, in terms of platelet count improvement and use of additional therapies, are identifiable from the first 6 months of treatment.
MoreTranslated text
Key words
eltrombopag,children,immune thrombocytopenia,thrombopoietin receptor agonists,bleeding disorders
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined